Low risk for de-novo IBD in patients treated with bariatric surgery, weight loss medications

Patients who are obese and underwent treatment with either bariatric surgery or weight-loss medications compared with persistently obese patients not exposed to either intervention are at lower risk for development of de-novo inflammatory bowel disease, according to study results.“Future research is needed to understand the mechanism behind persistent or refractory obesity and development of inflammatory bowel disease as this might provide insights into disease pathogenesis and global prevention strategies,” Gursimran S. Kochhar, MD, from the Division of Gastroenterology,Read More

Share on facebook
Share on twitter
Share on linkedin